{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:54:32Z","timestamp":1790351672455,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024679","name":"Advanz Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024679","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011805","name":"Advanz Pharm Corp Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011805","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.cmi.2024.09.031","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T18:19:30Z","timestamp":1728152370000},"page":"240-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["In\u00a0vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives"],"prefix":"10.1016","volume":"31","author":[{"given":"R\u00e9my A.","family":"Bonnin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Jeannot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Santerre Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Quevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Dortet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2024.09.031_bib1","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/S0140-6736(24)00876-6","article-title":"The scope of the antimicrobial resistance challenge","volume":"403","author":"Okeke","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2024.09.031_bib2","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1093\/jac\/dkab173","article-title":"Consumption of penicillins in the community, European Union\/european economic area, 1997-2017","volume":"76","author":"Bruyndonckx","year":"2021","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.09.031_bib3","doi-asserted-by":"crossref","first-page":"ii22","DOI":"10.1093\/jac\/dkab174","article-title":"Consumption of cephalosporins in the community, European union\/European economic area, 1997-2017","volume":"76","author":"Versporten","year":"2021","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.09.031_bib4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molmed.2012.03.003","article-title":"Carbapenem resistance in Enterobacteriaceae: here is the storm","volume":"18","author":"Nordmann","year":"2012","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.cmi.2024.09.031_bib5","article-title":"Beta-lactam resistance in Pseudomonas aeruginosa: current status","volume":"10","author":"Glen","year":"2021","journal-title":"Future Prospects Pathogens"},{"key":"10.1016\/j.cmi.2024.09.031_bib6","doi-asserted-by":"crossref","first-page":"7631","DOI":"10.2147\/IDR.S386641","article-title":"Molecular characterization of carbapenem-resistant Acinetobacter baumannii with special reference to carbapenemases: a systematic review","volume":"15","author":"Gupta","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.cmi.2024.09.031_bib7","series-title":"Activity report. CNR de la R\u00e9sistance Aux Antibiotiques","author":"Bonnet","year":"2023"},{"key":"10.1016\/j.cmi.2024.09.031_bib8","article-title":"Role of beta-lactamase inhibitors as potentiators in antimicrobial chemotherapy targeting Gram-negative bacteria","volume":"13","author":"Zhang","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2024.09.031_bib9","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/jac\/dkaa511","article-title":"An update on cefepime and its future role in combination with novel beta-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa","volume":"76","author":"Isler","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.09.031_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00105-19","article-title":"Beyond piperacillin-tazobactam: cefepime and AAI101 as a potent beta-lactam-beta-lactamase inhibitor combination","volume":"63","author":"Papp-Wallace","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.09.031_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00514-19","article-title":"In\u00a0vitro activity of cefepime-enmetazobactam against Gram-negative isolates collected from U.S. And European hospitals during 2014-2015","volume":"63","author":"Morrissey","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.09.031_bib12","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of cefepime\/enmetazobactam vs piperacillin\/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2024.09.031_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105925","article-title":"In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae","volume":"56","author":"Tselepis","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.09.031_bib14","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1099\/jmm.0.071340-0","article-title":"Impact of the isolation medium for detection of carbapenemase-producing Enterobacteriaceae using an updated version of the carba np test","volume":"63","author":"Dortet","year":"2014","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.cmi.2024.09.031_bib15","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1093\/jac\/dkac303","article-title":"Comparison of three lateral flow immunochromatographic assays for the rapid detection of KPC, NDM, IMP, VIM and OXA-48 carbapenemases in Enterobacterales","volume":"77","author":"Bernabeu","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.09.031_bib16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/dkv308","article-title":"Prospective evaluation of an algorithm for the phenotypic screening of carbapenemase-producing Enterobacteriaceae","volume":"71","author":"Dortet","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.09.031_bib17","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1016\/S2666-5247(23)00407-X","article-title":"Spread of carbapenemase-producing Morganella spp from 2013 to 2021: a comparative genomic study","volume":"5","author":"Bonnin","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.cmi.2024.09.031_bib18","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1093\/jac\/dkaa345","article-title":"Resfinder 4.0 for predictions of phenotypes from genotypes","volume":"75","author":"Bortolaia","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.09.031_bib19","series-title":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of mics and zone diameters, version 14.0","year":"2024"},{"key":"10.1016\/j.cmi.2024.09.031_bib20","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/jac\/dkab142","article-title":"Biochemical characterization of OXA-244, an emerging OXA-48 variant with reduced beta-lactam hydrolytic activity","volume":"76","author":"Rima","year":"2021","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.09.031_bib21","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3201\/eid2704.204459","article-title":"Emergence and polyclonal dissemination of OXA-244-producing Escherichia coli, France","volume":"27","author":"Emeraud","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2024.09.031_bib22","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3201\/eid2606.191517","article-title":"Emergence of new non-clonal group 258 high-risk clones among Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates, France","volume":"26","author":"Bonnin","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2024.09.031_bib23","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3201\/eid3006.231525","article-title":"IMI-type carbapenemase-producing Enterobacter cloacae complex, France and overseas regions, 2012-2022","volume":"30","author":"Emeraud","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2024.09.031_bib24","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2023.28.42.2300095","article-title":"Emergence and rapid dissemination of highly resistant NDM-14-producing Klebsiella pneumoniae ST147, France, 2022","volume":"28","author":"Emeraud","year":"2023","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2024.09.031_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106660","article-title":"Susceptibility of OXA-48-producing Enterobacterales to imipenem\/relebactam, meropenem\/vaborbactam and ceftazidime\/avibactam","volume":"60","author":"Bonnin","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.09.031_bib26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3390\/microorganisms10020258","article-title":"To be or not to be an OXA-48 carbapenemase","volume":"10","author":"Dabos","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.cmi.2024.09.031_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00008-23","article-title":"Klebsiella pneumoniae carbapenemase variants: the new threat to global public health","volume":"36","author":"Ding","year":"2023","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2024.09.031_bib28","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/jac\/dkz508","article-title":"Different phenotypic expression of KPC beta-lactamase variants and challenges in their detection","volume":"75","author":"Oueslati","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.09.031_bib29","series-title":"Aztreonam-avibactam and cefepime-enmetazobactam now available","year":"2024"},{"key":"10.1016\/j.cmi.2024.09.031_bib30","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/jac\/dkad400","article-title":"Characterization of VIM-29 and VIM-86, two VIM-1 variants isolated in multidrug-resistant Enterobacterales in France","volume":"79","author":"Rezzoug","year":"2024","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.09.031_bib31","series-title":"In vivo efficacy of enmetazobactam combined with cefepime in a neutropenic murine OXA-48 Klebsiella pneumoniae pneumonia model","author":"Albac","year":"2024"},{"key":"10.1016\/j.cmi.2024.09.031_bib32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.09.031_bib33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.09.031_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106776","article-title":"Activity of aztreonam\/avibactam against metallo-beta-lactamase-producing Enterobacterales from the UK: impact of penicillin-binding protein-3 inserts and CMY-42 beta-lactamase in Escherichia coli","volume":"61","author":"Livermore","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.09.031_bib35","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.3201\/eid2909.230390","article-title":"Population analysis of Escherichia coli sequence type 361 and reduced cefiderocol susceptibility, France","volume":"29","author":"Jousset","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2024.09.031_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.920319","article-title":"OXA-244-producing ST131 Escherichia coli from surface and groundwaters of Pavia urban area (po plain, Northern Italy)","volume":"13","author":"AbuAlshaar","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2024.09.031_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106157","article-title":"Cross-border emergence of clonal lineages of ST38 Escherichia coli producing the OXA-48-like carbapenemase OXA-244 in Germany and Switzerland","volume":"56","author":"Falgenhauer","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.09.031_bib38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12941-015-0108-y","article-title":"The spread of blaOXA-48 and blaOXA-244 carbapenemase genes among Klebsiella pneumoniae, Proteus mirabilis and Enterobacter spp. Isolated in Moscow, Russia","volume":"14","author":"Fursova","year":"2015","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.cmi.2024.09.031_bib39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jhin.2023.12.020","article-title":"Emergence and dissemination of epidemic-causing OXA-244 carbapenemase-producing Escherichia coli ST38 through hospital sewage in Norway, 2020-2022","volume":"145","author":"Grevskott","year":"2024","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.cmi.2024.09.031_bib40","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.18.1900742","article-title":"Surveillance of OXA-244-producing Escherichia coli and epidemiologic investigation of cases, Denmark, January 2016 to August 2019","volume":"25","author":"Hammerum","year":"2020","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2024.09.031_bib41","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.22.2300666","article-title":"Large hospital outbreak caused by OXA-244-producing Escherichia coli sequence type 38, Poland, 2023","volume":"29","author":"Izdebski","year":"2024","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2024.09.031_bib42","doi-asserted-by":"crossref","first-page":"2000923","DOI":"10.2807\/1560-7917.ES.2020.25.25.2000923","article-title":"Rapid spread of OXA-244-producing Escherichia coli ST38 in Germany: Insights from an integrated molecular surveillance approach; 2017 to January 2020","volume":"25","author":"Kremer","year":"2020","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2024.09.031_bib43","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2023.28.27.2200773","article-title":"Intraregional hospital outbreak of OXA-244-producing Escherichia coli ST38 in Norway, 2020","volume":"28","author":"Lindemann","year":"2023","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2024.09.031_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115059","article-title":"Ongoing dissemination of OXA-244 carbapenemase-producing Escherichia coli in Switzerland and their detection","volume":"97","author":"Masseron","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2024.09.031_bib45","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1093\/jac\/dkac307","article-title":"A genetic cluster of OXA-244 carbapenemase-producing Escherichia coli ST38 with putative uropathogenicity factors in The Netherlands","volume":"77","author":"Notermans","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.09.031_bib46","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/jac\/dks383","article-title":"Emergence of OXA-48-producing Klebsiella pneumoniae and the novel carbapenemases OXA-244 and OXA-245 in Spain","volume":"68","author":"Oteo","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.09.031_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmm.2023.151595","article-title":"Prolonged carriage of OXA-244-carbapenemase-producing Escherichia coli complicates epidemiological investigations","volume":"314","author":"Reichert","year":"2024","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.cmi.2024.09.031_bib48","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.46.2001815","article-title":"Emergence of carbapenem-resistant ST131 Escherichia coli carrying blaOXA-244 in Germany, 2019 to 2020","volume":"25","author":"Welker","year":"2020","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2024.09.031_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03223-23","article-title":"When the Trojan horse is unable to reach inside the city: investigation of the mechanism of resistance behind the first reported cefiderocol-resistant E. coli in Canada","volume":"12","author":"Barker","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2024.09.031_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1390966","article-title":"Characterizing carbapenemase-producing Escherichia coli isolates from Spain: high genetic heterogeneity and wide geographical spread","volume":"14","author":"Dahdouh","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.cmi.2024.09.031_bib51","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad276","article-title":"An NDM-producing Escherichia coli clinical isolate exhibiting resistance to cefiderocol and the combination of ceftazidime-avibactam and aztreonam: another step toward pan-beta-lactam resistance","volume":"10","author":"Simner","year":"2023","journal-title":"Open Forum Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24004786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24004786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T17:53:32Z","timestamp":1738432412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X24004786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1198743X24004786"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2024.09.031","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In\u00a0vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.09.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}